Dr. Kabakoff earned his Bachelor of Arts in Chemistry from Case Western Reserve University, his Ph.D. in Organic Chemistry from Yale University, and post-doctoral research at the University of California San Diego. He held senior executive positions with Syntex, Hybritech, Inc., Corvas International, Dura Pharmaceuticals and Spiros Development Corp. Dr. Kabakoff co-founded Salmedix and subsequently negotiated its acquisition by Cephalon, Inc. He has over 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical and drug delivery fields. He served as an Executive Partner with Sofinnova Ventures, Chairman of Trius Therapeutics, Chairman of Amplimmune, Inc., and Director of InterMune, Inc. and Allylix, Inc.
Interviewed by Mark Jones, PhD, UCSD
At the time of this interview, Dr. Kabakoff served in senior executive positions at Dura Pharmaceuticals Inc.